ADM
MCID: DRM010
MIFTS: 66

Dermatomyositis (ADM)

Categories: Bone diseases, Eye diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Dermatomyositis

MalaCards integrated aliases for Dermatomyositis:

Name: Dermatomyositis 12 77 54 55 60 56 45 15 17 74
Amyopathic Dermatomyositis 12 54 74
Adult Dermatomyositis 54 60
Polymyositis with Skin Involvement 12
Dermatomyositis Sine Myositis 54
Adult Type Dermatomyositis 74
Dermatopolymyositis 12
Adm 54

Characteristics:

Orphanet epidemiological data:

60
dermatomyositis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (Australia),1-9/100000 (Australia),1-9/1000000 (Argentina),1-5/10000 (Argentina),1-9/1000000 (United States),1-9/1000000 (Spain); Age of onset: All ages; Age of death: any age;

Classifications:



Summaries for Dermatomyositis

NINDS : 55 Dermatomyositis is one of a group of muscle diseases known as the inflammatory myopathies, which are characterized by chronic muscle inflammation accompanied by muscle weakness.  Dermatomyositis’ cardinal symptom is a skin rash that precedes, accompanies, or follows  progressive muscle weakness.  The rash looks patchy, with purple or red discolorations, and characteristically develops on the eyelids and on muscles used to extend or straighten joints, including knuckles, elbows, knees, and toes.  Red rashes may also occur on the face, neck, shoulders, upper chest, back, and other locations, and there may be swelling in the affected areas.  The rash sometimes occurs without obvious muscle involvement.  Adults with dermatomyositis may experience weight loss, a low-grade fever, inflamed lungs, and be sensitive to light such that the rash or muscle disease gets worse.  Children and adults with dermatomyositis may develop calcium deposits, which appear as hard bumps under the skin or in the muscle (called calcinosis).  Calcinosis most often occurs 1-3 years after the disease begins.  These deposits are seen more often in children with dermatomyositis than in adults.  In some cases of dermatomyositis, distal muscles (muscles located away from the trunk of the body, such as those in the forearms and around the ankles and wrists) may be affected as the disease progresses.  Dermatomyositis may be associated with collagen-vascular or autoimmune diseases, such as lupus. 

MalaCards based summary : Dermatomyositis, also known as amyopathic dermatomyositis, is related to polymyositis and psoriasis, and has symptoms including pruritus and exanthema. An important gene associated with Dermatomyositis is RN7SL1 (RNA Component Of Signal Recognition Particle 7SL1), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Pirfenidone and Abatacept have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and breast, and related phenotypes are emg abnormality and autoimmunity

Disease Ontology : 12 A myositis that results in inflammation located in muscle or located in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction.

NIH Rare Diseases : 54 Amyopathic dermatomyositis is a form of dermatomyositis characterized by the presence of typical skin findings without muscle weakness. Some of the skin changes that suggest dermatomyositis include a pink rash on the face, neck, forearms and upper chest; Gottron's papules and heliotrope eyelids. Pruritis and photosensitivity are common, as is scalp inflammation and thinning of the hair. While patients with amyopathic dermatomyositis should not have clinically evident muscle weakness, minor muscle abnormalities may be included. Fatigue is reported in at least 50% of patients. Some cases have been associated with internal malignancy and/or interstitial lung disease. Treatment may include sun avoidance, ample use of sunscreen, topical corticosteroids, antimalarial agents, methotrexate, mycophenolate mofetil, or intravenous (IV) immunoglobulin.

Wikipedia : 77 Dermatomyositis (DM) is a long-term inflammatory disorder which affects muscles. Its symptoms are... more...

Related Diseases for Dermatomyositis

Diseases in the Dermatomyositis family:

Adult Dermatomyositis

Diseases related to Dermatomyositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 505)
# Related Disease Score Top Affiliating Genes
1 polymyositis 30.8 MIR130A MIR132 MIR146B MIR155 MIR21 MIR210
2 psoriasis 30.0 MIR146B MIR21 MIR381 MIR99B
3 melanoma 29.8 MIR154 MIR199B MIR210 MIR221 MIR222
4 nonalcoholic fatty liver disease 29.6 MIR130A MIR132 MIR154 MIR21
5 inclusion body myositis 29.3 MIR146B MIR155 MIR21 MIR214 MIR221 MIR222
6 diffuse large b-cell lymphoma 29.0 MIR155 MIR21 MIR210 MIR221
7 lung cancer 28.9 MIR130A MIR146B MIR155 MIR199B MIR21 MIR210
8 prostate cancer 28.5 MIR199B MIR21 MIR210 MIR214 MIR221 MIR222
9 leukemia, acute myeloid 28.5 MIR130A MIR155 MIR199B MIR21 MIR210 MIR221
10 hepatocellular carcinoma 28.4 MIR130A MIR132 MIR148B MIR155 MIR199B MIR21
11 ovarian cancer 28.4 MIR146B MIR155 MIR199B MIR21 MIR210 MIR214
12 pancreatic cancer 28.1 MIR148B MIR155 MIR21 MIR210 MIR214 MIR221
13 muscular dystrophy, duchenne type 27.6 MIR130A MIR146B MIR154 MIR199B MIR21 MIR210
14 childhood type dermatomyositis 12.8
15 adult dermatomyositis 12.3
16 neonatal dermatomyositis 12.2
17 complement component 9 deficiency 11.8
18 myositis 11.7
19 idiopathic inflammatory myopathy 11.4
20 hypertension, essential 11.4
21 antisynthetase syndrome 11.4
22 congestive heart failure 11.3
23 cerebrovascular disease 11.2
24 vitreoretinopathy, neovascular inflammatory 11.2
25 pre-eclampsia 11.2
26 renal hypertension 11.2
27 renovascular hypertension 11.2
28 arteriosclerosis 11.2
29 acute pyelonephritis 11.2
30 macular holes 11.2
31 myeloproliferative syndrome, transient 11.1
32 endocrine organ benign neoplasm 11.1
33 cardiovascular system disease 11.1
34 adrenomyeloneuropathy 11.1
35 al amyloidosis 11.1
36 idiopathic edema 11.1
37 lung disease 10.7
38 interstitial lung disease 10.7
39 calcinosis 10.6
40 breast reconstruction 10.5
41 pneumonia 10.5
42 lupus erythematosus 10.5
43 arthritis 10.4
44 systemic lupus erythematosus 10.3
45 lymphoma 10.3
46 panniculitis 10.3
47 breast cancer 10.2
48 vasculitis 10.2
49 rheumatoid arthritis 10.2
50 nasopharyngeal carcinoma 10.2

Comorbidity relations with Dermatomyositis via Phenotypic Disease Network (PDN):


Acute Cystitis Polymyositis

Graphical network of the top 20 diseases related to Dermatomyositis:



Diseases related to Dermatomyositis

Symptoms & Phenotypes for Dermatomyositis

Human phenotypes related to Dermatomyositis:

60 33 (show top 50) (show all 51)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 emg abnormality 60 33 hallmark (90%) Very frequent (99-80%) HP:0003457
2 autoimmunity 60 33 hallmark (90%) Very frequent (99-80%) HP:0002960
3 myalgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003326
4 erythema 60 33 hallmark (90%) Very frequent (99-80%) HP:0010783
5 periorbital edema 60 33 hallmark (90%) Very frequent (99-80%) HP:0100539
6 proximal muscle weakness 60 33 hallmark (90%) Very frequent (99-80%) HP:0003701
7 inflammatory myopathy 60 33 hallmark (90%) Very frequent (99-80%) HP:0009071
8 abnormal eyelid morphology 33 hallmark (90%) HP:0000492
9 muscular hypotonia 60 33 frequent (33%) Frequent (79-30%) HP:0001252
10 respiratory insufficiency 60 33 frequent (33%) Frequent (79-30%) HP:0002093
11 arthritis 60 33 frequent (33%) Frequent (79-30%) HP:0001369
12 recurrent respiratory infections 60 33 frequent (33%) Frequent (79-30%) HP:0002205
13 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
14 pulmonary fibrosis 60 33 frequent (33%) Frequent (79-30%) HP:0002206
15 arthralgia 60 33 frequent (33%) Frequent (79-30%) HP:0002829
16 acrocyanosis 60 33 frequent (33%) Frequent (79-30%) HP:0001063
17 abnormality of the nail 60 33 frequent (33%) Frequent (79-30%) HP:0001597
18 pruritus 60 33 frequent (33%) Frequent (79-30%) HP:0000989
19 weight loss 60 33 frequent (33%) Frequent (79-30%) HP:0001824
20 dry skin 60 33 frequent (33%) Frequent (79-30%) HP:0000958
21 skin ulcer 60 33 frequent (33%) Frequent (79-30%) HP:0200042
22 abnormal hair quantity 60 33 frequent (33%) Frequent (79-30%) HP:0011362
23 papule 60 33 frequent (33%) Frequent (79-30%) HP:0200034
24 chondrocalcinosis 60 33 frequent (33%) Frequent (79-30%) HP:0000934
25 interstitial pulmonary abnormality 60 33 frequent (33%) Frequent (79-30%) HP:0006530
26 diffuse reticular or finely nodular infiltrations 60 33 frequent (33%) Frequent (79-30%) HP:0002207
27 dysphonia 60 33 occasional (7.5%) Occasional (29-5%) HP:0001618
28 feeding difficulties in infancy 60 33 occasional (7.5%) Occasional (29-5%) HP:0008872
29 fever 60 33 occasional (7.5%) Occasional (29-5%) HP:0001945
30 myocardial infarction 60 33 occasional (7.5%) Occasional (29-5%) HP:0001658
31 pulmonary arterial hypertension 60 33 occasional (7.5%) Occasional (29-5%) HP:0002092
32 lung adenocarcinoma 60 33 occasional (7.5%) Occasional (29-5%) HP:0030078
33 telangiectasia of the skin 60 33 occasional (7.5%) Occasional (29-5%) HP:0100585
34 aplasia/hypoplasia of the skin 60 33 occasional (7.5%) Occasional (29-5%) HP:0008065
35 pericarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0001701
36 myocarditis 60 33 occasional (7.5%) Occasional (29-5%) HP:0012819
37 cellulitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0100658
38 vasculitis 60 33 occasional (7.5%) Occasional (29-5%) HP:0002633
39 lymphoma 60 33 occasional (7.5%) Occasional (29-5%) HP:0002665
40 breast carcinoma 60 33 occasional (7.5%) Occasional (29-5%) HP:0003002
41 cutaneous photosensitivity 60 33 occasional (7.5%) Occasional (29-5%) HP:0000992
42 gangrene 60 33 occasional (7.5%) Occasional (29-5%) HP:0100758
43 sinus tachycardia 60 33 occasional (7.5%) Occasional (29-5%) HP:0011703
44 gastrointestinal stroma tumor 60 33 occasional (7.5%) Occasional (29-5%) HP:0100723
45 abnormal eosinophil morphology 33 occasional (7.5%) HP:0001879
46 arrhythmia 60 Occasional (29-5%)
47 neoplasm 60 Occasional (29-5%)
48 edema 60 Very frequent (99-80%)
49 abnormality of the eyelid 60 Very frequent (99-80%)
50 abnormality of the voice 60 Occasional (29-5%)

UMLS symptoms related to Dermatomyositis:


pruritus, exanthema

Drugs & Therapeutics for Dermatomyositis

Drugs for Dermatomyositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pirfenidone Approved, Investigational Phase 4,Phase 3 53179-13-8 40632
2
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
3 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Vaccines Phase 4,Not Applicable
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
12 beta-endorphin Phase 4,Phase 2
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Melanocyte-Stimulating Hormones Phase 4,Phase 2
15 Adrenocorticotropic Hormone Phase 4,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
19
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2 2921-57-5
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
23
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
24
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
25
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2 302-25-0
26
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
27
Etanercept Approved, Investigational Phase 2, Phase 3,Phase 1 185243-69-0
28
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
29
tannic acid Approved Phase 2, Phase 3 1401-55-4
30
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
31
Alendronate Approved Phase 2, Phase 3 66376-36-1, 121268-17-5 2088
32
Infliximab Approved Phase 2, Phase 3 170277-31-3
33
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
34
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
35
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
36
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
38
Prednisolone hemisuccinate Experimental Phase 3,Phase 2 2920-86-7
39 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Not Applicable
40 Antimetabolites, Antineoplastic Phase 3,Phase 2
41 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
42 Folate Phase 3,Phase 2
43 Antiemetics Phase 3,Phase 2
44 Methylprednisolone Acetate Phase 3,Phase 2
45 Vitamin B9 Phase 3,Phase 2
46 Folic Acid Antagonists Phase 3,Phase 2
47 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
48 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
49 Calcineurin Inhibitors Phase 3,Phase 2
50 Protective Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 101)
# Name Status NCT ID Phase Drugs
1 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
4 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
5 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
6 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Completed NCT03226119 Phase 4
7 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
8 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Recruiting NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
9 Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis Terminated NCT03686969 Phase 3 Octanorm
10 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Active, not recruiting NCT02728752 Phase 3 Octagam 10%
11 Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) Recruiting NCT03857854 Phase 3 Pirfenidone;Placebos
12 Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis Terminated NCT00035958 Phase 2, Phase 3 Prednisone;Methotrexate;Etanercept
13 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
14 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
15 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
16 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
17 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
18 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
19 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
20 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
21 Belimumab in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
22 A Clinical Trial for CTD-ILD Treatment Terminated NCT01424033 Phase 2, Phase 3 N-Acetylcysteine
23 Abatacept Treatment in Polymyositis and Dermatomyositis Unknown status NCT01315938 Phase 2 Abatacept;Abatacept
24 Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis Recruiting NCT03529955 Phase 2 Apremilast 30mg
25 Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis Active, not recruiting NCT02466243 Phase 2 JBT-101;Placebo
26 Trial of IMO-8400 in Adult Patients With Dermatomyositis Completed NCT02612857 Phase 2 IMO-8400 Dose Group 1;IMO-8400 Dose Group 2;Placebo
27 A Study In Adults With Moderate To Severe Dermatomyositis Recruiting NCT03181893 Phase 2 PF-06823859;Placebo Arm
28 Topical Sodium Thiosulfate and Fractional Carbon Dioxide Laser in Treating Dermatomyositis Associated Calcinosis Completed NCT01572844 Phase 2 Sodium thiosulfate
29 Study of IFN-K in Dermatomyositis Recruiting NCT02980198 Phase 2
30 Acthar in Treatment of Refractory Dermatomyositis and Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
31 Safety and Efficacy of BAF312 in Dermatomyositis Terminated NCT02029274 Phase 2 BAF312;Placebo
32 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Recruiting NCT02043548 Phase 2 tocilizumab;placebo
33 Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
34 Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis Completed NCT00005571 Phase 2 h5G1.1-mAb
35 Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis Completed NCT01415219 Phase 2
36 Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis Terminated NCT01148810 Phase 2 BAF312;Placebo
37 Methimazole to Treat Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
38 Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
39 Absorption of Corticosteroids in Children With Juvenile Dermatomyositis Completed NCT00004357 Phase 2 Methylprednisolone;Prednisolone
40 Basiliximab Treating Interstitial Pneumonia of CADM Not yet recruiting NCT03192657 Phase 2 Basiliximab;Calcineurin Inhibitors;Steroids
41 Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Completed NCT00106184 Phase 2 Rituximab;Placebo
42 Intralesional Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study Not yet recruiting NCT03582800 Phase 2 STS
43 Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Completed NCT00001261 Phase 2 Gamma Globulin
44 A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
45 A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis Withdrawn NCT01918904 Phase 2 Sodium thiosulfate;Placebo
46 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
47 Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders Not yet recruiting NCT02418273 Phase 1, Phase 2 denosumab
48 Study of Tofacitinib in Refractory Dermatomyositis Recruiting NCT03002649 Phase 1 Tofacitinib
49 A Pilot Study of Etanercept in Dermatomyositis Completed NCT00112385 Phase 1 Etanercept;Placebo
50 A Study to Evaluate Safety of Multi-Dose MEDI-545 in Adult Patients With Dermatomyositis or Polymyositis Completed NCT00533091 Phase 1

Search NIH Clinical Center for Dermatomyositis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: dermatomyositis

Genetic Tests for Dermatomyositis

Anatomical Context for Dermatomyositis

MalaCards organs/tissues related to Dermatomyositis:

42
Lung, Skin, Breast, T Cells, Bone, Thyroid, B Cells

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatomyositis:

20
Muscle Or

Publications for Dermatomyositis

Articles related to Dermatomyositis:

(show top 50) (show all 3399)
# Title Authors Year
1
The IgG2 isotype of anti-transcription intermediary factor 1-gamma autoantibodies is a biomarker of mortality in adult dermatomyositis. ( 30896088 )
2019
2
Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. ( 30766892 )
2019
3
FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis. ( 30879053 )
2019
4
Giant thoracic calcinosis: a dermatomyositis manifestation. ( 30715552 )
2019
5
Relative risk of microscopic colitis in dermatomyositis. ( 30910660 )
2019
6
Gastric cancer and paraneoplastic dermatomyositis as complications of an unrecognized juvenile polyposis syndrome. ( 30873576 )
2019
7
Serum KL-6 is associated with the severity of interstitial lung disease in Chinese patients with polymyositis and dermatomyositis. ( 30888566 )
2019
8
Small cell lung cancer and interstitial pneumonia associated with anti-transcriptional intermediary factor-1γ-positive dermatomyositis. ( 30906559 )
2019
9
Global analysis of protein expression in muscle tissues of dermatomyositis/polymyosisits patients demonstrated an association between dysferlin and human leucocyte antigen A. ( 30907425 )
2019
10
Dermatomyositis. ( 30910882 )
2019
11
Specific Autoantibodies and Clinical Phenotypes Correlate with the Aberrant Expression of Immune-Related MicroRNAs in Dermatomyositis. ( 30915368 )
2019
12
The diagnostic value of T2 maps and rs-EPI DWI in dermatomyositis. ( 30383453 )
2019
13
Hemophagocytic Lymphohistiocytosis in Dermatomyositis ( 30457107 )
2019
14
Dermatomyositis associated with omalizumab therapy for severe asthma: a case report. ( 30675173 )
2019
15
Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases. ( 30740105 )
2019
16
Skin inflammation associated with arthritis, synovitis and enthesitis. Part 2: rheumatoid arthritis, reactive arthritis, Reiter's syndrome, Lyme borreliosis, dermatomyositis and lupus erythematosus. ( 30762968 )
2019
17
Hautentzündungen mit Arthritis, Synovitis und Enthesitis. Teil 2: Rheumatoide Arthritis, reaktive Arthritis, Morbus Reiter, Lyme-Borreliose, Dermatomyositis und Lupus erythematodes. ( 30762961 )
2019
18
Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture. ( 30766682 )
2019
19
Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. ( 30243657 )
2019
20
Juvenile dermatomyositis associated with anti-melanoma differentiation-associated gene 5 antibody positivity without complications of interstitial lung disease during the clinical course: A case report. ( 30869164 )
2019
21
Juvenile dermatomyositis with IgA nephropathy: case-based review. ( 30552457 )
2019
22
Prognosis of dysphagia in dermatomyositis. ( 30557132 )
2019
23
Toxic epidermal necrolysis-like dermatomyositis associated with antimelanoma differentiation antigen 5. ( 30581943 )
2019
24
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. ( 30608616 )
2019
25
Clinical value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. ( 30614031 )
2019
26
Successful Treatment for Refractory Interstitial Lung Disease and Pneumomediastinum With Multidisciplinary Therapy Including Tofacitinib in a Patient With Anti-MDA5 Antibody-Positive Dermatomyositis. ( 30614890 )
2019
27
ASYMPTOMATIC MULTIFOCAL PARACENTRAL ACUTE MIDDLE MACULOPATHY ASSOCIATED WITH JUVENILE DERMATOMYOSITIS: OPTICAL COHERENCE ANGIOGRAPHY FINDINGS. ( 30614926 )
2019
28
French expert opinion for the management of juvenile dermatomyositis. ( 30638764 )
2019
29
Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis. ( 30647164 )
2019
30
Superior Mesenteric Artery Syndrome in a Case of Juvenile Dermatomyositis: A Unique Complication. ( 30664541 )
2019
31
Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. ( 30673076 )
2019
32
Examining Cutaneous Disease Activity As An Outcome Measure For Clinical Trials In Dermatomyositis. ( 30685266 )
2019
33
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. ( 30690571 )
2019
34
Atrophic palmar papules in lupus erythematosus: are inverse Gottron papules specific for dermatomyositis? ( 30690634 )
2019
35
A case of dermatomyositis with the anti-signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy. ( 30690762 )
2019
36
Co-existence of Juvenile dermatomyositis and psoriasis vulgaris with fungal infection: A case report and literature review. ( 30697901 )
2019
37
The Association of Short-term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis. ( 30714338 )
2019
38
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. ( 30715143 )
2019
39
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. ( 30715158 )
2019
40
Elevated plasma D-dimer levels in dermatomyositis patients with cutaneous manifestations. ( 30723246 )
2019
41
Clinical Factors Associated with Cutaneous Histopathologic Findings in Dermatomyositis. ( 30737826 )
2019
42
Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. ( 30739212 )
2019
43
The pulseless patient: Profound vasculopathy as the presenting feature of fulminant dermatomyositis and response to therapy. ( 30740501 )
2019
44
Apremilast as a potential treatment for moderate to severe dermatomyositis: A retrospective study of 3 patients. ( 30740504 )
2019
45
Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. ( 30746580 )
2019
46
Infliximab improved the refractory cutaneous involvement in a patient with dermatomyositis. ( 30748085 )
2019
47
Paraneoplastic dermatomyositis presenting with interesting cutaneous findings. ( 30758348 )
2019
48
EBV-Associated Non-keratinizing Nasopharyngeal Carcinoma with Prominent Spindled Cell and Whorling Patterns: A Previously Unreported Histological Variant in a Patient Presenting with Dermatomyositis. ( 30758756 )
2019
49
Detection of serum MCP-1 and TGF-β1 in polymyositis/dermatomyositis patients and its significance. ( 30764873 )
2019
50
Tracking changes nailfold capillary abnormalities in Dermatomyositis on treatment. ( 30776398 )
2019

Variations for Dermatomyositis

Expression for Dermatomyositis

Search GEO for disease gene expression data for Dermatomyositis.

Pathways for Dermatomyositis

Pathways related to Dermatomyositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.64 MIR155 MIR199B MIR21 MIR210 MIR214 MIR221
2 11.03 MIR210 MIR221 MIR222
3 10.81 MIR221 MIR222
4 10.71 MIR146B MIR221 MIR222

GO Terms for Dermatomyositis

Cellular components related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 MIR130A MIR132 MIR146B MIR148B MIR155 MIR199B
2 micro-ribonucleoprotein complex GO:0035068 9.6 MIR130A MIR132 MIR146B MIR148B MIR154 MIR155

Biological processes related to Dermatomyositis according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.94 MIR132 MIR155 MIR21 MIR214
2 positive regulation of protein kinase B signaling GO:0051897 9.88 MIR132 MIR199B MIR21 MIR221 MIR222
3 negative regulation of angiogenesis GO:0016525 9.83 MIR21 MIR214 MIR222
4 negative regulation of inflammatory response GO:0050728 9.82 MIR155 MIR221 MIR222
5 positive regulation of epithelial to mesenchymal transition GO:0010718 9.77 MIR21 MIR221 MIR222
6 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR146B MIR155 MIR221 MIR495
7 negative regulation of sprouting angiogenesis GO:1903671 9.75 MIR221 MIR487B MIR495
8 negative regulation of vascular endothelial cell proliferation GO:1905563 9.74 MIR132 MIR487B MIR495
9 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.73 MIR155 MIR222 MIR495
10 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.73 MIR214 MIR221 MIR222 MIR495
11 positive regulation of angiogenesis GO:0045766 9.73 MIR130A MIR132 MIR199B MIR21 MIR210 MIR99B
12 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.69 MIR155 MIR221 MIR222
13 positive regulation of cardiac muscle cell proliferation GO:0060045 9.68 MIR199B MIR222
14 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.68 MIR132 MIR487B
15 positive regulation of epithelial cell migration GO:0010634 9.68 MIR221 MIR222
16 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.68 MIR199B MIR21
17 positive regulation of erythrocyte differentiation GO:0045648 9.67 MIR221 MIR222
18 positive regulation of activated T cell proliferation GO:0042104 9.67 MIR155 MIR21
19 positive regulation of cardiac muscle hypertrophy GO:0010613 9.67 MIR155 MIR21
20 positive regulation of endothelial cell differentiation GO:0045603 9.67 MIR199B MIR21 MIR99B
21 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.66 MIR21 MIR221
22 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.66 MIR132 MIR487B
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.65 MIR21 MIR214
24 positive regulation of connective tissue replacement GO:1905205 9.64 MIR155 MIR214
25 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.63 MIR155 MIR214
26 negative regulation by host of viral genome replication GO:0044828 9.63 MIR221 MIR222
27 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.62 MIR21 MIR210
28 positive regulation of axon regeneration GO:0048680 9.62 MIR221 MIR222
29 positive regulation of vascular endothelial cell proliferation GO:1905564 9.62 MIR130A MIR132 MIR21 MIR495
30 negative regulation of regulatory T cell differentiation GO:0045590 9.61 MIR155 MIR21
31 negative regulation of artery morphogenesis GO:1905652 9.61 MIR487B MIR495
32 gene silencing by miRNA GO:0035195 9.6 MIR130A MIR132 MIR146B MIR148B MIR154 MIR155
33 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.59 MIR221 MIR222
34 positive regulation of vascular smooth muscle cell dedifferentiation GO:1905176 9.58 MIR214 MIR221
35 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.58 MIR155 MIR221 MIR222
36 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.55 MIR221 MIR222
37 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.55 MIR130A MIR21 MIR214 MIR221 MIR222
38 positive regulation of Schwann cell migration GO:1900149 9.54 MIR221 MIR222
39 negative regulation of cell adhesion molecule production GO:0060354 9.54 MIR155 MIR221 MIR222
40 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.52 MIR221 MIR222
41 miRNA mediated inhibition of translation GO:0035278 9.43 MIR132 MIR155 MIR21 MIR210 MIR221 MIR222

Molecular functions related to Dermatomyositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.44 MIR130A MIR132 MIR146B MIR148B MIR155 MIR199B

Sources for Dermatomyositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....